(Q36621961)

15 August 2017

1 reference

title

Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs (English)

1 reference

15 August 2017

1 reference

Douglas M Potter

1

1 reference

15 August 2017

publication date

1 January 2006

1 reference

Journal of Biopharmaceutical Statistics

15 August 2017

published in

1 reference

15 August 2017

volume

16

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

579-604

1 reference

Ethics of phase 1 oncology studies: reexamining the arguments and data

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

First-time-in-human dose selection: allometric thoughts and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Determining a maximum-tolerated schedule of a cytotoxic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

On the use of nonparametric curves in phase I trials with low toxicity tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

The continual reassessment method in cancer phase I clinical trials: a simulation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Designs for single- or multiple-agent phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Phase I trial design: are new methodologies being put into practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

A curve-free method for phase I clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Some practical improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Adaptive design improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

A non-parametric approach to the design and analysis of two-dimensional dose-finding trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

A comparison of two phase I trial designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Longitudinal design for phase I clinical trials using the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

A logistic dose-ranging method for phase I clinical investigations trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Another look at two phase I clinical trial designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Continual reassessment designs with early termination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Curve-free and model-based continual reassessment method designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Retrospective analysis of sequential dose-finding designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Continual reassessment method for ordered groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Continual reassessment method: a practical design for phase 1 clinical trials in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Continual reassessment method: a likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Quantile estimation following non-parametric phase I clinical trials with ordinal response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Practical implementation of a modified continual reassessment method for dose-finding trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Improved designs for dose escalation studies using pharmacokinetic measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

A Stochastic Approximation Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Competing designs for phase I clinical trials: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Design and analysis of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

An evaluation of phase I clinical trial designs in the continuous dose-response setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Estimating the probability of toxicity at the target dose following an up-and-down design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Accrual strategies for phase I trials with delayed patient outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Dose‐Finding with Two Agents in Phase I Oncology Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Bayesian decision procedures for dose determining experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400600860295

10.1080/10543400600860295

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference